Clay Siegall is the co-founder of Seattle Genetics according to an article from Crunchbase and is the president of it. He has also served on the Board of Directors for various companies. Seattle Genetics produces antibody-based cancer therapies including one called ADCETRIS that was granted approval by the U.S. Food and Drug Administration. Siegall has led Seattle Genetics down a road of success as he made the company more than $675 million through public and private financing.
Prior to being the president of Seattle Genetics, he was apart of the Bristol-Myers Squibb Pharmaceutical Research Institute from the years 1991 to 1997, along with the National Cancer Insitute and Health from 1988 to 1991. Along with being a businessman, he is even an author and has more than 70 publications and holds 15 patents. Clay Siegall has a ph.D. in Genetics from George Washington University, along with a B.S. in Zoology out of the University of Maryland. The business owner has won awards while at schools such as winning Alumnus of the year for Computer, Math, and Natural Sciences while at the University of Maryland and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the year.
An article by Ideamensch goes into the mission of Seattle Genetics and business strategies in a small interview conducted with the entrepreneur Clay Siegall. The entrepreneur got the idea to start his own brand after witnessing his own father succumb to cancer and the limited sources available at the time. The main objective of his company is to help patients with cancer and treat them to the best of their ability. As an entrepreneur, he gives the advice to keep learning and working with others who are intellectual. He makes an interesting statement that we never stop learning and even if we think we know it all we still don’t. Clay Seigall ends the interview on a note that colloborating with others and extending the reach of technology to help patients.